AZD4956 + Saruparib for Cancer

(PARTHENON Trial)

This trial explores a new cancer treatment by testing different doses of a drug called AZD4956, both alone and in combination with saruparib (a type of cancer therapy), to assess their safety and effectiveness. It targets individuals with advanced or metastatic solid tumors, particularly those with specific genetic vulnerabilities in their cancers. Those with advanced breast, ovarian, or prostate cancer who have not received certain other treatments might be suitable candidates. As a Phase 1 trial, the research aims to understand how the treatment works in people, providing participants the opportunity to be among the first to receive this new treatment.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research is investigating AZD4956 as a single treatment to determine its safety and tolerability in patients with advanced or spreading solid tumors. Since AZD4956 remains in the early stages of human testing, researchers are still gathering and studying detailed safety information.

When combined with saruparib, studies are assessing how well patients tolerate this treatment. Early results indicate that researchers are monitoring for side effects, though specific details are not yet fully available. This combination targets tumors with certain genetic traits, making safety understanding crucial.

For saruparib alone, evidence suggests it is generally well-tolerated. Reports indicate that saruparib is safe with a wide range between effective and harmful doses. However, like many treatments, it can cause side effects such as tiredness and nausea.

Researchers are excited about AZD4956 and saruparib because these treatments offer a novel approach to cancer therapy. Unlike traditional chemotherapy that attacks all rapidly dividing cells, AZD4956 is being explored for its potential to precisely target cancer cells while sparing healthy ones. Saruparib, on the other hand, is a promising PARP inhibitor, which interferes with cancer cells' ability to repair their DNA, making them more vulnerable to damage. This combination is particularly intriguing as it could enhance the effectiveness of treatment by using two complementary mechanisms, potentially leading to better outcomes for patients with fewer side effects.

This trial will evaluate AZD4956 and saruparib in different treatment arms. Studies have shown that AZD4956 targets tumors with specific genetic defects common in some cancers. This approach exploits the cancer cells' inability to repair DNA properly, potentially stopping their growth. In this trial, some participants will receive AZD4956 as monotherapy, while others will receive it combined with saruparib. Research indicates that combining AZD4956 with saruparib, a drug that has shown promising results in prostate and breast cancers, might enhance effectiveness. Studies on saruparib alone have demonstrated its efficacy in patients with advanced cancers, with nearly half responding positively. These findings suggest that using AZD4956 and saruparib together could effectively treat cancers with these genetic defects.⁴⁶⁷⁸⁹